HollyTM Implantable Continuous Dialysis System Could be Ready for Human Trials Soon

The device, granted FDA breakthrough status last December, may be ready for human testing in 20-24 months. Besides being a bridge to transplant, it can improve quality of life for those who do not qualify for a transplant.

Read the full article » | Posted 04-14-2026

Related Articles

• The Lancet Digital Health published results of Humacyte’s Phase III clinical trial of its V007 acellular tissue engineered vessel (ATEV) HD access Posted 09-18-2026
• Humacyte, Inc. announced Robert J. Kossman, MD, FACP, FASN and Prabir Roy-Chaudhury, MD, PhD, FASN have joined the company as advisors. Posted 08-21-2026
• Byonyks on the Move: X-2 and X-3 APD Devices in Development Posted 07-16-2026
• Dr. Ben Reynolds and the Virtual Reality Kidney Dialysis Training Project Posted 06-17-2026